Study of Adebrelimab With Apatinib and Chemotherapy for Untreatable Biliary Tract Cancer in Adults

What this Trial Is About

Researchers are investigating treatment options for patients with biliary tract tumors that cannot be removed by surgery and have not been treated before. This exploratory study evaluates the effects and safety of a combination therapy using Adebrelimab, a monoclonal antibody, together with targeted therapy and chemotherapy. The goal is to understand how well this combined treatment works for these patients. Participants receive Adebrelimab through an intravenous infusion of 1200 mg on the first day of each 3-week cycle. Alongside this, they get Gemcitabine at 1000 mgm2 on days 1 and 8, and Cisplatin at 50 mgm2 on day 1, both repeated every 3 weeks. Additionally, Apatinib is taken orally at 250 mg once daily. This treatment plan continues through multiple cycles to assess effectiveness and safety. During the study, patients are monitored regularly, with assessments at the end of cycles 6 and 10, each lasting 21 days, to measure the overall response rate. Researchers also track disease control, progression-free survival, adverse events, and overall survival over periods up to 24 months. Participants undergo various evaluations including physical exams and lab tests, and their health is followed closely to understand treatment impact over time. The study is planned to continue until late 2028.

A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer